Analysis: Nectar Lifesciences Limited

NSE:NECLIFE Pharma - API Market cap: ₹238 cr

Research report

companyname: Nectar Lifesciences Limited ticker: NECLIFE sector: Pharmaceuticals / Real Estate Nectar Lifesciences Limited (NLL / Neclife / Nectar) is an Indian company that has undergone a fundamental transformation during FY 2025-26. The company historically operated as a global pharmaceutical manufacturer with a focus on cephalosporin antibiotics. During the year, it divested its pharmaceutical businesses through a slump sale and is now transitioning towards real estate activities. The comp...

Read the full report →
RS rating: 70 Stage: Stage 1

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Nectar Lifesciences Limited and 4,900+ companies.

Sign in
5-day free pass. No card required.